Impact of DBLG1 Hybrid Closed‐Loop Software Optimization and Meal Declaration Pattern on Glucose Metrics in Type 1 Diabetes: A 12‐Month Prospective Evaluation in 2014 Users
Open Access
- 19 October 2026
- journal article
- Published by Wiley in Diabetes, Obesity and Metabolism
Abstract
Background: The meal period is critical for the outcome of automated insulin delivery. Our aim was to explore the long‐term impact on glucose metrics of algorithmic modifications of the DBLG1 hybrid closed‐loop system, with special emphasis on the meal declaration pattern. Methods: We prospectively analysed CGM data from consenting adult patients with Type 1 diabetes across Europe who initiated the new version of DBLG1 paired with the Kaleido patch pump upon its release. Inclusion occurred over 7 months, with follow‐up extended up to 12 months. Time in range 70–180 mg/dL (TIR) was the primary endpoint. Utility endpoints included the number of declared meals. Results: This study included 2014 users, age 42.5 ± 13.8 years, baseline HbA1c 7.6% ± 1.2%. Median TIR was 72.0%, 72.3%, 72.0% and 71.7% at M3, M6, M9 and M12, respectively. At M3, time < 54 mg/dL (0.2%), < 70 mg/dL (1.2%) and > 250 mg/dL (5.4%) were controlled and remained stable throughout M12, as well as GMI (7.0%–7.1%). The incidence rates of severe hypo‐ or hyperglycaemia remained very low. TIR in patients declaring ≥ 3 meals/day exceeded TIR in those declaring < 1 meal/day (73.3 [67.3, 78.7]% vs. 65.7 [60.7, 72.2]%, p < 0.0001). Conclusion: This study demonstrates the sustained safety and effectiveness of the latest version of the DBLG1 software, with TIR exceeding 70% throughout the 12‐month follow‐up period in a large group of 2014 users. Furthermore, while glycaemic control was negatively affected when meal declaration was reduced, the software maintained its safety and acceptable effectiveness in this latter situation.Keywords
This publication has 26 references indexed in Scilit:
- Fully closed-loop systems: can people with type 1 diabetes just do it? Insights from open-source systemsDiabetologia, 2026
- Automated insulin delivery: benefits, challenges, and recommendations. A Consensus Report of the Joint Diabetes Technology Working Group of the European Association for the Study of Diabetes and the American Diabetes AssociationDiabetologia, 2022
- Multicenter, Randomized Trial of a Bionic Pancreas in Type 1 DiabetesNew England Journal of Medicine, 2022
- Hybrid closed-loop insulin delivery versus sensor-augmented pump therapy in children aged 6–12 years: a randomised, controlled, cross-over, non-inferiority trialThe Lancet Digital Health, 2022
- Real-World Performance of the MiniMed™ 780G System: First Report of Outcomes from 4120 UsersDiabetes Technology & Therapeutics, 2022
- One Year Real-World Use of the Control-IQ Advanced Hybrid Closed-Loop TechnologyDiabetes Technology & Therapeutics, 2021
- A comparison of two hybrid closed-loop systems in adolescents and young adults with type 1 diabetes (FLAIR): a multicentre, randomised, crossover trialThe Lancet, 2021
- Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 DiabetesNew England Journal of Medicine, 2019
- Closed-loop insulin delivery in adults with type 1 diabetes in real-life conditions: a 12-week multicentre, open-label randomised controlled crossover trialThe Lancet Digital Health, 2019
- Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: a multicentre, 12-week randomised trialThe Lancet, 2018